Klotho Peptide

Alpha-Klotho (hereafter Klotho) is a 1,012 amino acid type I transmembrane glycoprotein that was originally discovered in 1997 by Makoto Kuro-o, who named it after the Greek Fate who spins the thread of life. The discovery came from a chance insertion event in mice that caused premature aging: mice homozygous for the Klotho hypomorphic mutation develop a syndrome resembling accelerated human aging, including arteriosclerosis, osteoporosis, skin atrophy, emphysema, hypogonadism, and cognitive decline, dying at 60 days (vs 120 days for wild-type). Conversely, mice overexpressing Klotho live 20-30% longer than controls - one of the most dramatic lifespan extension results achieved by any single genetic manipulation in mammals.

Klotho exists in multiple forms with distinct biology. Membrane Klotho (mKlotho) is expressed at highest levels in the kidney tubule, choroid plexus of the brain, and parathyroid gland. The extracellular domain can be shed by ADAM10 and ADAM17 metalloprotease cleavage to produce soluble Klotho (sKlotho) that circulates in blood and CSF. A shorter form (s-form) arises from alternative splicing. The circulating sKlotho concentration (~300-800 pg/mL in healthy young adults) appears to be a relevant biomarker: it declines progressively with age, is reduced in chronic kidney disease, and correlates positively with cognitive performance in multiple human cohort studies.

The molecular functions of Klotho are multiple and interconnected. The membrane form acts as a co-receptor for FGF23 (fibroblast growth factor 23), a bone-derived hormone that regulates phosphate excretion by the kidneys and suppresses vitamin D activation. Without Klotho as an obligatory co-receptor, the FGFR/FGF23 complex cannot form, and phosphate regulation fails - producing the hyperphosphataemia that drives cardiovascular calcification in CKD. This Klotho-FGF23 axis is now a central focus of nephrology and cardiovascular research, with Klotho levels serving as one of the earliest and most sensitive biomarkers of kidney decline.

The soluble form of Klotho has FGF23-independent actions that are equally important for its anti-aging properties. sKlotho acts as a humoral factor (a true circulating hormone) that binds to and modifies cell surface receptors and signalling pathways throughout the body. Key mechanisms include: (1) Wnt/beta-catenin pathway inhibition - excessive Wnt signalling drives cellular senescence and fibrosis in aging tissues, and sKlotho suppresses this by binding and sequestering Wnt ligands; (2) IGF-1/PI3K/Akt pathway modulation - Klotho reduces excessive insulin-like growth factor signalling that accelerates aging in multiple longevity models; (3) Nrf2 antioxidant pathway activation - sKlotho induces expression of antioxidant enzymes (SOD, catalase, GPx) reducing oxidative stress in aging organs.

The cognitive effects of Klotho have emerged as a major research frontier following a landmark 2014 paper by Dubal and colleagues in Cell Reports. Mice with heterozygous Klotho overexpression (approximately 1.5-2x normal Klotho levels) show superior performance on multiple hippocampal learning and memory tasks. These cognitive benefits are mediated by increased synaptic GluN2B-containing NMDA receptors in the hippocampus, which enhance LTP magnitude. Critically, the cognitive benefits of Klotho overexpression are preserved even in the context of Alzheimer's pathology (expressed in APP/PS1 mice), suggesting Klotho can counteract amyloid-induced cognitive decline.

The single-injection reversal of cognitive aging in aged mice and non-human primates deserves special attention. A single IV injection of purified recombinant Klotho protein in aged (>18 years old) rhesus monkeys produced dose-dependent improvements in working memory performance lasting at least 2 weeks. Given that a single injection could measurably improve cognitive function in an aged primate without prior cognitive impairment, the implications for human healthy aging are profound if these results translate. Multiple pharmaceutical companies are now developing stabilised Klotho fragments, small molecule Klotho enhancers, and Klotho gene therapy approaches for both Alzheimer's disease and healthy cognitive aging.